DEFA14A ·Filed Apr 21, 2026
Proxy solicitation materials
Actionable Insight • Neutral
This is a routine filing. No immediate action or trading read-through is expected. Monitor the next 10-Q for any potential changes in business outlook.
Price Chart
Loading chart...
Executive Summary
Ligand Pharmaceuticals Inc. has filed a definitive proxy statement (DEFA14A) for its upcoming annual shareholder meeting. This routine filing details matters to be voted on, such as director elections and executive compensation, and is standard for public companies.
Key Financial Metrics
Vote
director election
Key Facts
- Company: Ligand Pharmaceuticals Inc. (Ticker: LGNZZ)
- Form Type: DEFA14A (Definitive Proxy Statement)
- Filing Date: 2026-04-21
- Document Type: Routine proxy statement for an annual shareholder meeting
Financial Impact
No material financial impact. This is a standard, non-material filing.
Market Snapshot
Exchange
OTC
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0000886163-26-000022 |
| Document: 0000886163-26-000022-index-headers.html | 0000886163-26-000022 |
| Document: 0000886163-26-000022-index.html | 0000886163-26-000022 |
| Document: 0000886163-26-000022.txt | 0000886163-26-000022 |
US Market Status
Market Closed — Opens Wed (16h 25m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers